Overview
Danaher Q3 revenue up 4.5% yr/yr to $6.1 bln, beating analysts' expectations
Adjusted EPS for Q3 at $1.89, exceeding expectations
Company attributes growth to bioprocessing and higher-than-expected respiratory revenue at Cepheid
Outlook
Danaher maintains full-year adjusted EPS guidance of $7.70 to $7.80
Company expects low-single digit core revenue growth for 2025
Danaher anticipates 2.5% sales increase from currency impact in Q4 2025
Result Drivers
BIOPROCESSING MOMENTUM - Co cites strong performance in bioprocessing as a key driver of Q3 results
RESPIRATORY REVENUE - Higher-than-expected respiratory revenue at Cepheid contributed to exceeding expectations
DBS EXECUTION - Co attributes exceeding expectations to DBS-driven execution
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $6.10 bln | $6 bln (18 Analysts) |
Q3 Adjusted EPS | Beat | $1.89 | $1.72 (19 Analysts) |
Q3 EPS | $1.27 | ||
Q3 Operating Cash Flow | $1.70 bln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for $Danaher Corp(DHR-W)$ is $240.00, about 13.2% above its October 20 closing price of $208.39
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 24 three months ago
Press Release: ID:nPn1V157qa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)